Anti–PD-1 Immunotherapy in NSCLC With BRAF, HER2, or MET Mutation or RET-Translocation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology